Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Jurg M Sommer"'
Autor:
Garabet G Toby, Tongyao Liu, Yang Buyue, Xin Zhang, Alan J Bitonti, Glenn F Pierce, Jurg M Sommer, Haiyan Jiang, Robert T Peters
Publikováno v:
PLoS ONE, Vol 11, Iss 2, p e0148255 (2016)
INTRODUCTION:Hemophilia B is an inherited X chromosome-linked disorder characterized by impaired blood clotting owing to the absence of functional coagulation factor IX. Due to the relatively short half-life of factor IX, patients with hemophilia B r
Externí odkaz:
https://doaj.org/article/58c4ecd32473436ca225422f97a166da
Autor:
Yang Buyue, Tongyao Liu, John D Kulman, Garabet G Toby, George D Kamphaus, Susannah Patarroyo-White, Qi Lu, Thomas J Reidy, Baisong Mei, Haiyan Jiang, Glenn F Pierce, Jurg M Sommer, Robert T Peters
Publikováno v:
PLoS ONE, Vol 9, Iss 11, p e113600 (2014)
Recombinant factor VIII Fc (rFVIIIFc) is a fusion protein consisting of a single B-domain-deleted (BDD) FVIII linked recombinantly to the Fc domain of human IgG1 to extend half-life. To determine if rFVIIIFc could be further improved by maintaining t
Externí odkaz:
https://doaj.org/article/9f7063df33694e378018959bd4c66d30
Autor:
Joe Salas, Tongyao Liu, Randy Mauldin, Jiayun Liu, Terrence M. Dobrowsky, Jurg M. Sommer, Volker Schellenberger, Susannah Patarroyo-White, Mark Tie, Ayman Ismail, Buyue Yang, Haiyan Jiang, Arjan van der Flier, Qi Lu, Chris Furcht, Nancy Moore, Tyler Carlage, John Kulman, Baisong Mei, Amy M Holthaus, Allison Goodman, Zhan Liu, Lily Zhu, Robert T. Peters, Deana Rabinovich, Glenn F. Pierce, Ekta Seth Chhabra, Douglas Drager, Oblaise Mercury, Zhiqian Liu
Publikováno v:
Blood
Factor VIII (FVIII) replacement products enable comprehensive care in hemophilia A. Treatment goals in severe hemophilia A are expanding beyond low annualized bleed rates to include long-term outcomes associated with high sustained FVIII levels. Endo
Publikováno v:
International Journal of Laboratory Hematology
Introduction The one‐stage clotting assay is used to measure factor IX (FIX) activity in patients’ plasma samples and in FIX products for hemophilia treatment. However, the diversity of reagents and instruments has resulted in significant FIX ass
Publikováno v:
Blood Coagulation & Fibrinolysis
The aim of this study was to compare the hemostatic efficacy of recombinant factor VIII Fc (rFVIIIFc) (Eloctate) and Advate by ex-vivo rotation thromboelastometry (ROTEM) of whole blood and to explore potential ROTEM parameters that may be more predi
Autor:
Annemieke J. Willemze, Margareta Wikén, Ali Sadeghi-Khomami, Jurg M. Sommer, Christopher Barnowski
Publikováno v:
International Journal of Laboratory Hematology
Introduction Monitoring of factor IX (FIX) replacement therapy in haemophilia B relies on accurate coagulation assays. However, considerable interlaboratory variability has been reported for one‐stage clotting (OSC) assays. This study aimed to eval
Autor:
Johnny, Mahlangu, Jerry S, Powell, Margaret V, Ragni, Pratima, Chowdary, Neil C, Josephson, Ingrid, Pabinger, Hideji, Hanabusa, Naresh, Gupta, Roshni, Kulkarni, Patrick, Fogarty, David, Perry, Amy, Shapiro, K John, Pasi, Shashikant, Apte, Ivan, Nestorov, Haiyan, Jiang, Shuanglian, Li, Srividya, Neelakantan, Lynda M, Cristiano, Jaya, Goyal, Jurg M, Sommer, Jennifer A, Dumont, Nigel, Dodd, Karen, Nugent, Gloria, Vigliani, Alvin, Luk, Aoife, Brennan, Glenn F, Pierce, Michael, Guerrera
Publikováno v:
Blood. 123:317-325
This phase 3 pivotal study evaluated the safety, efficacy, and pharmacokinetics of a recombinant FVIII Fc fusion protein (rFVIIIFc) for prophylaxis, treatment of acute bleeding, and perioperative hemostatic control in 165 previously treated males age
Autor:
Barbara A. Konkle, Glenn F. Pierce, Nancy Moore, Jurg M. Sommer, B McGuffie-Valentine, Yang Buyue, George D. Kamphaus, Sara Bardan
Publikováno v:
Haemophilia
Discrepancies exist for some of the modified coagulation factors when assayed with different one-stage clotting and chromogenic substrate assay reagents. The aim of this study was to evaluate the performance of a recombinant factor VIII Fc fusion pro
Autor:
Haiyan Jiang, Justin McCue, Jennifer A. Dumont, Margaret V. Ragni, Alvin Luk, Glenn F. Pierce, Jaya Goyal, Doris Quon, Ella Li, Neil C. Josephson, Gregory Cheng, Jurg M. Sommer, Xin Zhang, Jerry S. Powell, Margaret Barbetti, Li Lian
Publikováno v:
Blood. 119:3031-3037
Current factor VIII (FVIII) products display a half-life (t1/2) of ∼ 8-12 hours, requiring frequent intravenous injections for prophylaxis and treatment of patients with hemophilia A. rFVIIIFc is a recombinant fusion protein composed of a single mo
Autor:
Olga Zelenaia, Katherine A. High, Pete Smith, Guang Qu, Jurg M. Sommer, Xingge Liu, Federico Mingozzi, Samuel L. Murphy, J. Fraser Wright, Bernd Hauck
Publikováno v:
Molecular Therapy. 17:144-152
In a gene therapy clinical trial for hemophilia B, adeno-associated virus 2 (AAV2) capsid-specific CD8(+) T cells were previously implicated in the elimination of vector-transduced hepatocytes, resulting in loss of human factor IX (hFIX) transgene ex